Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Affiliations

• ¹ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. icglitza@mdanderson.org.
• ² Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁷ Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁰ Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
• ¹¹ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.